Contents

QazCovid-in

Part of a series on the
COVID-19 pandemic
COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November December 2023
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Endemic phase Evacuations Face masks International aid Origin Lockdowns by country Misinformation by governments Fake treatments Social distancing Software Travel United Nations World Health Organization WTO IP waiver Undercounting of deaths COVID-19 apps Zero-COVID National responses Africa China European Union Germany Ghana India Ireland Netherlands New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Public health mitigation Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Food security Journalism Music Performing arts Retail Shipping Television US sportscasting programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US By sport Association football Baseball Basketball Combat sports Cricket Disc golf Gaelic games Gridiron football Ice hockey Motorsport Rugby league
Impacts Animals Alzheimer's disease patients Black people Crime Death rates by country Disability Domestic violence Emergency evacuations Education Female Environment Hospitals Language LGBT community Long-term care Media coverage Mental health symptoms Migration Military Notable deaths Other health issues Politics diplomacy Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Strikes Suicides Telehealth Xenophobia and racism Society Ireland Malaysia New Zealand Russia UK US
COVID-19 portal
v t e

QazCovid-in, commercially known as QazVac,^[1][2] is a COVID-19 vaccine developed by the Research Institute for Biological Safety Problems in Kazakhstan.^[3][4] QazCoVac-P is a second COVID-19 vaccine developed by the Kazakh Biosafety Research Institute and in clinical trials.^[5]

Manufacturing[edit]

The vaccine can be stored at standard refrigeration temperatures (2 °C-8 °C) and is a two-dose régime with the doses administered twenty-one days apart.^[6] The vaccine was first manufactured by Kazakhstan's Research Institute of Biological Safety Problems. Production capacity has been capped at 50,000 doses per month.^{[citation needed]}

Beginning in June 2021, the vaccine is slated^[7] to be packaged in large bulk to be bottled in Turkey by a major Turkish company.^[8] This will allow for a production capacity of 500,000-600,000 doses per month.^[9] The contract is still being negotiated,^[10] despite earlier claims suggesting that the deal had already been finalized.^[11][12]

In October 2021, it was announced that the vaccine would be supplied to Afghanistan and other countries in 2022.^[13]

History[edit]

Clinical trials[edit]

In September 2020, QazVac started in Phase I/II clinical trials.^[14]

In December 2020, QazVac is currently in Phase III clinical trials, which is expected to be fully completed by 9 July 2021.^[2][8] It is unclear when the first preliminary results will be published.^[15][12]

The administration of the vaccine for the general population began at the end of April 2021.^[16] The Research Institute Kunsulu Zakarya's Director General's justification is that the trial is almost 50% completed and "people who have received [the] vaccine feel well; there have been no side-effects and the effectiveness of the vaccine is high".^[8]

In September 2021, a study was published to eClinicalMedicine, published by The Lancet. The study’s findings were that the “QazCovid-in® vaccine was safe and well-tolerated and induced predominantly mild adverse events; no serious or severe adverse events were recorded in both trials.” ^[17]

Authorization[edit]

Economics[edit]

The first batch of 50,000 doses was delivered on 26 April 2021, and vaccination began shortly after.^{[citation needed]} In June 2021, the capacity will increase to 100,000 doses per month, regardless of the contract for bottling in Turkey.^[18]

References[edit]

External links[edit]

Scholia has a profile for QazCovid-in (Q99518269).

Viruses

COVID-19